Freeline_Logo_Red_RGB.jpg
Freeline Reports Half Year 2020 Financial Results and Recent Business Highlights
October 29, 2020 16:15 ET | Freeline Therapeutics
Will report updated durability data from Phase 1/2 B-AMAZE trial in Haemophilia B in Q4 Third wholly-owned programme expected to be in the clinic in 2021 Strong cash position with over $250 million...
Freeline_Logo_Red_RGB.jpg
Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference at the revised time of 3.45 pm EDT on 6 October
September 29, 2020 07:00 ET | Freeline Therapeutics
LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline_Logo_Red_RGB.jpg
Freeline announces promotion of Romuald Corbau, Ph.D. to Chief Scientific Officer
September 28, 2020 07:00 ET | Freeline Therapeutics
LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic, AAV-based...
Freeline_Logo_Red_RGB.jpg
Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference
September 25, 2020 07:00 ET | Freeline Therapeutics
LONDON, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline_Logo_Red_RGB.jpg
Freeline announces supply agreement for haemophilia B program
September 23, 2020 07:00 ET | Freeline Therapeutics
LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, fully-integrated, next generation, systemic, AAV-based...
Freeline_Logo_Red_RGB.jpg
Freeline to participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
September 10, 2020 07:00 ET | Freeline Therapeutics
LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline_Logo_Red_RGB.jpg
Freeline Announces Pricing of Initial Public Offering
August 07, 2020 02:49 ET | Freeline Therapeutics
LONDON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (“Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the...
Freeline_Logo_Red_RGB.jpg
Freeline Launches Roadshow for Initial Public Offering
August 03, 2020 06:30 ET | Freeline Therapeutics
LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (“Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the...
Freeline_Logo_Red_RGB.jpg
Freeline files registration statement for proposed initial public offering in the United States
July 20, 2020 02:00 ET | Freeline Therapeutics
LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of...
Freeline_Logo_Red_RGB.jpg
Freeline presents new Haemophilia B data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
July 13, 2020 11:45 ET | Freeline Therapeutics
- Updated FLT180a data in the B-AMAZE study in severe Haemophilia B patients demonstrated the potential for sustained normal FIX activity levels - - Additional data were presented in 5 poster...